BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd
BGLC•Form 3 filing shows Fidelion Diagnostics as greater-than-5% holder
BioNexus Gene Lab filed a Form 3 showing Fidelion Diagnostics beneficially owns 392,329 common shares as of Nov. 28, 2025.
The filing classifies Fidelion Diagnostics as a greater-than-5% holder. No derivative securities were reported.
The Form 3 was signed by Ling Xiao on Aug. 4, 2026.
